News|Articles|September 12, 2017

EMA Hosts Antimicrobial Resistance Meeting

The meeting, to be held jointly with the European Centre for Disease Prevention and Control, is part of the agency’s effort to raise awareness about the threat of antimicrobial resistance.

On Sept. 12, 2017, the European Medicines Agency (EMA) announced a joint meeting with the European Centre for Disease Prevention and Control (ECDC), to be held on Sept. 19, 2017 in London, to discuss the threat of antimicrobial resistance. The meeting will be attended by representatives of the World Health Organization, the European Commission, European Union Member States, patients’ and consumers’ organizations, healthcare professionals, and academics.

The purpose of the meeting is to raise awareness of the threat of antimicrobial resistance and to understand how EMA and ECDC can support European healthcare initiatives against the threat. According to EMA, the threat is rising, with a growing number of infections becoming increasingly resistant to antibiotics. This resistance makes treatment difficult, and EMA and other agencies feel the fight requires a global collaboration.

The draft agenda for the meeting includes overviews of EMA’s and ECDC’s efforts and how other organizations can join in with those efforts. The meeting will be broadcast live on EMA’s website, and a report will be published after the event.

Source: EMA


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.